Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C5H13N2O4P |
| Molecular Weight | 196.1415 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O
InChI
InChIKey=BHAYDBSYOBONRV-IUYQGCFVSA-N
InChI=1S/C5H13N2O4P/c1-3(6)5(8)7-4(2)12(9,10)11/h3-4H,6H2,1-2H3,(H,7,8)(H2,9,10,11)/t3-,4+/m0/s1
| Molecular Formula | C5H13N2O4P |
| Molecular Weight | 196.1415 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Alafosfalin is a phosphonodipeptide with significant activity as an antibacterial agent and as a potentiator of beta-lactam antibiotics. Alafosfalin shows good activity both in vitro and in vivo, particularly against Enterobacteriaceae. The compound acts by interfering with bacterial cell wall biosynthesis and also potentiates the activity of beta-lactam antibiotics. Alafosfalin was found to be highly active against Escherichia coli and moderately active against Serratia, Klebsiella, Enterobacter, and Citrobacter, but less active against gram-positive organisms than were beta-lactams such as cephazolin or ampicillin and inactive against indole-positive Proteus, Pseudomonas, and Acinetobacter.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Activity of a peptidyl prodrug, alafosfalin, against anaerobic bacteria. | 1985-06 |
|
| Pharmacokinetics of alafosfalin, alone and in combination with cephalexin, in humans. | 1980-06 |
|
| Alafosfalin, a new inhibitor of cell wall biosynthesis: in vitro activity against urinary isolates in Japan and potentiation with beta-lactams. | 1979-10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7406481
Studies in humans showed that oral doses of 50 to 2,500 mg were well absorbed, but some metabolic hydrolysis occurred before the drug reached the general circulation. Oral bioavailability was approximately 50% and was largely independent of dose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/518073
E.coli were the most susceptible to alafosfalin among all species, among 144 isolates, 93 and 86% of the strains were inhibited by 12.5 and 1.56 ug/ml, respectively, whereas the MIC50 was 0.39 ug/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:09:25 GMT 2025
by
admin
on
Wed Apr 02 09:09:25 GMT 2025
|
| Record UNII |
0M8OM373BS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C258
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C006437
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
100000087710
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
60668-24-8
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
C74137
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
DTXSID6046393
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
Alafosfalin
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
0M8OM373BS
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
262-362-8
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
SUB05289MIG
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL334756
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
m1465
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
4540
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY | |||
|
71957
Created by
admin on Wed Apr 02 09:09:25 GMT 2025 , Edited by admin on Wed Apr 02 09:09:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |